Inspection Reports and Proprietary Information

Following the FDA’s new agreement to share full inspection reports related to biosimilar manufacturing site to the European Medicines Agency, Molly Burich, MS; Amanda Forys, MSPH; and Ha Kung Wong, JD, remark on industry concerns surrounding confidentiality.
November 13, 2017
View Text Version
x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.